In an interview with BioPharma BoardRoom, Eric Blair, GDMC’s Chief Business Officer, discusses the company's strategic use of Series A funding to pio...
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion...
Viz.ai, a pioneering force in AI-driven disease detection and intelligent care coordination, has attained a significant milestone with the receipt ...
Takeda unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...
The amalgamation of Cytiva's pioneering technologies with LevitasBio's cutting-edge solutions seeks to streamline single-cell workflows, offering invaluabl...
In a landmark move within the life sciences sector, Novo Holdings has announced its acquisition of Catalent, Inc. in an all-cash transaction valued at $16....
In a groundbreaking initiative poised to revolutionize cancer treatment, AstraZeneca announces a strategic $300 million investment in a cutting-edge facili...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
Designed to overcome challenges in high-throughput screening for drug discovery, the Echo® MS+ system eliminates the need for extensive method developm...
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East...
Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene. From M...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Embracing the latest technology trends, LPH 1.0 represents a significant leap forward, with an upgrade to HTML5 browser-based technology. This advancement ...
© 2025 Biopharma Boardroom. All Rights Reserved.
